Related references
Note: Only part of the references are listed.Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Stopping Denosumab
Olivier Lamy et al.
CURRENT OSTEOPOROSIS REPORTS (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Cancer Treatment and Bone Health
Catherine Handforth et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
Anne M. Horne et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates
Liana Tripto-Shkolnik et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Effects and management of denosumab discontinuation
Roland Chapurlat
JOINT BONE SPINE (2018)
Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report
Olivier Lamy et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
T. Lehmann et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Elena Tsourdi et al.
BONE (2017)
Bone Loss After Denosumab: Only Partial Protection with Zoledronate
Ian R. Reid et al.
CALCIFIED TISSUE INTERNATIONAL (2017)
Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
B. Aubry-Rozier et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Share Paper
